First line therapy: have we made any improvement?

被引：5

作者：

Bookman, Michael A. ^{[1
]}

机构：

[1] Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85721 USA

来源：

EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷

关键词：

D O I：

10.1016/S0959-8049(11)70153-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：S93 / S103

页数：11

共 36 条

[1] Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
Alberts, DS
Liu, PY
Hannigan, EV
OToole, R
Williams, SD
Young, JA
Franklin, EW
ClarkePearson, DL
Malviya, VK
DuBeshter, B
Adelson, MD
Hoskins, WJ
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) : 1950 - 1955
[2] [Anonymous], J CLIN ONCOL
[3] [Anonymous], 2010, Cancer Facts Figures 2010
[4] Intraperitoneal cisplatin and paclitaxel in ovarian cancer
Armstrong, DK
Bundy, B
Wenzel, L
Huang, HQ
Baergen, R
Lele, S
Copeland, LJ
Walker, JL
Burger, RA
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) : 34 - 43
[5] Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study
Bolis, G
Danese, S
Tateo, S
Rabaiotti, E
D'Agostino, G
Merisio, C
Scarfone, G
Polverino, G
Parazzini, F
[J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 : 74 - 78
[6] Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study
Bolis, Giorgio
Scarfone, Giovanna
Raspagliesi, Francesco
Mangili, Giorgia
Danese, Saverio
Scollo, Paolo
Lo Russo, Domenica
Villa, Antonella
Aimone, Paola Daniela
Scambia, Giovanni
[J]. EUROPEAN JOURNAL OF CANCER, 2010, 46 (16) : 2905 - 2912
[7] Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
Bookman, Michael A.
Brady, Mark F.
McGuire, William P.
Harper, Peter G.
Alberts, David S.
Friedlander, Michael
Colombo, Nicoletta
Fowler, Jeffrey M.
Argenta, Peter A.
De Geest, Koen
Mutch, David G.
Burger, Robert A.
Swart, Ann Marie
Trimble, Edward L.
Accario-Winslow, Chrisann
Roth, Lawrence M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) : 1419 - 1425
[8] Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian trials in ovarian cancer (MITO-1) randomized study
De Placido, S
Scambia, G
Di Vagno, G
Naglieri, E
Lombardi, AV
Biamonte, R
Marinaccio, M
Carteni, G
Manzione, L
Febbraro, A
de Matteis, A
Gasparini, G
Valerio, MR
Danese, S
Perrone, F
Lauria, R
De Laurentiis, M
Greggi, S
Gallo, C
Pignata, S
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) : 2635 - 2642
[9] Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: A prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens
du Bois, A
Weber, B
Rochon, J
Meier, W
Goupil, A
Bricht, S
Barats, JC
Kuhn, W
Orfeuvre, H
Wagner, U
Richter, B
Lueck, HJ
Pfisterer, J
Costa, S
Schroeder, W
Kimmig, R
Pujade-Lauraine, E
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) : 1127 - 1135
[10] A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer
du Bois, A
Lück, HJ
Meier, W
Adams, HP
Möbus, V
Costa, S
Bauknecht, T
Richter, B
Warm, M
Schröder, W
Olbricht, S
Nitz, U
Jackisch, C
Emons, G
Wagner, U
Kuhn, W
Pfisterer, J
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (17): : 1320 - 1330

← 1 2 3 4 →